Abstract
The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin. One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study. Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1 mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2 mg three times a day for 12 months in a randomized, single-blind, controlled study. We evaluated at the baseline and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA 1c, glycemic control, fasting plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR) index, adiponectin, tumor necrosis factor-α, and high sensitivity-C reactive protein. Both treatments gave a similar improvement of glycemic control, without any differences between the two groups. Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein. Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride. We can conclude that exenatide was better than glimepiride in improving insulin resistance and inflammatory state. Furthermore, adiponectin increase, and tumor necrosis factor-α reduction seem to be related to weight loss obtained with exenatide.
| Original language | English |
|---|---|
| Pages (from-to) | 251-256 |
| Number of pages | 6 |
| Journal | European Journal of Pharmacology |
| Volume | 666 |
| Issue number | 1-3 |
| DOIs | |
| Publication status | Published - Sep 2011 |
Fingerprint
Keywords
- Adiponectin
- Exenatide
- Glimepiride
- Insulin resistance
- Tumor necrosis factor-a
ASJC Scopus subject areas
- Pharmacology
Cite this
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. / Derosa, Giuseppe; Putignano, Pietro; Bossi, Antonio C.; Bonaventura, Aldo; Querci, Fabrizio; Franzetti, Ivano G.; Guazzini, Barbara; Testori, Gianpaolo; Fogari, Elena; Maffioli, Pamela.
In: European Journal of Pharmacology, Vol. 666, No. 1-3, 09.2011, p. 251-256.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients
AU - Derosa, Giuseppe
AU - Putignano, Pietro
AU - Bossi, Antonio C.
AU - Bonaventura, Aldo
AU - Querci, Fabrizio
AU - Franzetti, Ivano G.
AU - Guazzini, Barbara
AU - Testori, Gianpaolo
AU - Fogari, Elena
AU - Maffioli, Pamela
PY - 2011/9
Y1 - 2011/9
N2 - The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin. One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study. Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1 mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2 mg three times a day for 12 months in a randomized, single-blind, controlled study. We evaluated at the baseline and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA 1c, glycemic control, fasting plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR) index, adiponectin, tumor necrosis factor-α, and high sensitivity-C reactive protein. Both treatments gave a similar improvement of glycemic control, without any differences between the two groups. Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein. Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride. We can conclude that exenatide was better than glimepiride in improving insulin resistance and inflammatory state. Furthermore, adiponectin increase, and tumor necrosis factor-α reduction seem to be related to weight loss obtained with exenatide.
AB - The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin. One hundred and eleven patients with uncontrolled type 2 diabetes mellitus and intolerant to metformin at the highest dosages (2500-3000 mg/day) were enrolled in this study. Patients were randomized to receive exenatide 5 μg twice a day or glimepiride 1 mg three times a day and titrated after 1 month to exenatide 10 μg twice a day or glimepiride 2 mg three times a day for 12 months in a randomized, single-blind, controlled study. We evaluated at the baseline and after 3, 6, 9, and 12 months these parameters: body weight, body mass index (BMI), HbA 1c, glycemic control, fasting plasma insulin, homeostasis model assessment insulin resistance index (HOMA-IR) index, adiponectin, tumor necrosis factor-α, and high sensitivity-C reactive protein. Both treatments gave a similar improvement of glycemic control, without any differences between the two groups. Only exenatide gave a decrease of BMI, insulin resistance parameters such as fasting plasma insulin, HOMA-IR, and adiponectin and a decrease of inflammatory parameters such as tumor necrosis factor-α, and high sensitivity-C reactive protein. Furthermore, the values obtained with exenatide were significantly better than the values recorded with glimepiride. We can conclude that exenatide was better than glimepiride in improving insulin resistance and inflammatory state. Furthermore, adiponectin increase, and tumor necrosis factor-α reduction seem to be related to weight loss obtained with exenatide.
KW - Adiponectin
KW - Exenatide
KW - Glimepiride
KW - Insulin resistance
KW - Tumor necrosis factor-a
UR - http://www.scopus.com/inward/record.url?scp=79959975635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959975635&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2011.05.051
DO - 10.1016/j.ejphar.2011.05.051
M3 - Article
C2 - 21645507
AN - SCOPUS:79959975635
VL - 666
SP - 251
EP - 256
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
IS - 1-3
ER -